Posts Tagged oxycontin

BCBS Alabama to No Longer Cover OxyContin Beginning in 2019

BCBS Alabama to No Longer Cover OxyContin Beginning in 2019

BIRMINGHAM, AL – Effective Jan. 1, 2019, Blue Cross Blue Shield of Alabama will no longer cover OxyContin for members with the exception of Blue Advantage members. This is in response to concerns for members’ care and safety.

Since 2015, opioid prescriptions in the U.S. and in Alabama have declined. Over the last two years, opioid prescriptions for BCBS Alabama’s commercial members have decreased 18 percent. While progress is being made, this issue calls for continued action by all parties.

Beginning Jan. 1, 2019, the following changes to Blue Cross’ Opioid Management Strategy for commercial members will be implemented:

  • Roxybond, the new instant release oxycodone formulation that is considered “abuse deterrent” by the FDA, will be covered.
  • Lucemyra (lofexidine), the first non-opioid approved drug to treat the symptoms of opioid withdrawal, will be covered.
  • OxyContin, and its generic (oxycodone ER), will no longer be covered. Xtampza ER (oxycodone ER) will be available to all members at a non-preferred brand cost share.

Letters have been mailed to members receiving OxyContin or oxycodone ER notifying them of the change and recommending that they follow up with their doctor to discuss potential alternatives. Providers have also been notified with a list of covered alternatives.

Several alternatives will be covered at the lowest copay for members who need a long-acting opioid for around the clock pain management: Morphine ER, Tramadol ER, Fentanyl ER and Methadone will be covered.

Blue Cross always encourages its members to consult their doctors about any treatments or prescription drugs they may need, and the company relies on physicians’ expertise to know what is best for their patients. Blue Cross will continue to develop and adopt actionable policies and procedures that promote safe prescribing of opioid medication and appropriate access to treatment for opioid use disorder. In addition, we will continue to collaborate with Alabama physicians and pharmacists to help curb the growing epidemic of opioid misuse by offering support, resources, and educational tools to network providers. This, combined with our strategies to improve access to medications used to treat substance abuse and drug overdoses, demonstrate our commitment to the health of our membership.

Posted in: Opioid

Leave a Comment (0) →

State of Alabama Files Lawsuit Against Purdue Pharma

State of Alabama Files Lawsuit Against Purdue Pharma

MONTGOMERY – The State of Alabama has joined other states in filing a complaint against opioid manufacturer Purdue Pharma, LP, one of the largest opioid manufacturers in the country. The complaint alleges Purdue’s marketing of these drugs contributed to the creation of the opioid epidemic in Alabama.

The lawsuit comes on the heels of a report by the Alabama Opioid Overdose and Addiction Council, appointed by Gov. Kay Ivey in mid-2017 to devise solutions to the state’s opioid crisis.

That report found at least 30,000 Alabama residents over the age of 17 are dependent on heroin or prescription painkillers. The council also found the drug overdose death rate in Alabama also increased 82 percent from 2006 to 2014. During that period, 5,128 people died from overdoses. In the U.S, more than 42,000 overdose deaths in 2016 involved opioids, according to the Centers for Disease Control and Prevention.

The lawsuit alleges that marketers persuaded physicians that prescription painkillers were not addictive, according to Alabama Attorney General Steve Marshall.

“The lies that they were told and trained in over the years whether it be that there was no dosage too high of an opioid … or even this concept of a pseudo-addiction that if somebody appeared in an office demonstrating signs of addiction that just meant that they needed more pain medication,” AG Marshall said.

Purdue denies the allegations, writing in a statement that its drugs are approved by the Food and Drug Administration and make up only 2 percent of all opioids prescribed.

Purdue Pharma manufactures, markets and sells prescription opioid pain medications, including the brand name drugs OxyContin, MS Contin, Dilaudid/Dilaudid HP, Butrans, Hysingla ER and Targiniq ER, as well as generic opioids. OxyContin constitutes roughly 30 percent of the entire market for analgesic drugs (painkillers). Purdue’s drugs compose a majority of the extended release market, for use with chronic non-cancer pain patients, which is the most dangerous method of use. Prescription opioids constitute the largest component of the opioid epidemic, both in quantity and damage caused.

Posted in: Opioid

Leave a Comment (0) →

STUDY: Opioid Abuse Drops When Doctors Check Patients’ Drug History

STUDY: Opioid Abuse Drops When Doctors Check Patients’ Drug History

ITHACA, N.Y. – There’s a simple way to reduce the opioid epidemic gripping the country, according to new Cornell University research: Make doctors check their patients’ previous prescriptions.

The most significant response to the opioid epidemic comes from state governments. Nearly every state now has a database that tracks every prescription for opioids like OxyContin, Percocet and Vicodin. Using these databases, doctors and pharmacists can retrieve a patient’s history to decide whether they are an opioid abuser before prescribing them drugs.

Such databases reduce opioid abuse among Medicare recipients – but only when laws require doctors to consult them, according to a Cornell health care economist and her colleague. Their study refutes previous research suggesting the databases have no effect on opioid abuse. The paper is forthcoming in the American Economic Journal: Economic Policy.

“The main issue is getting providers to change their prescribing behavior. The majority of opioids that people abuse start in the medical system as a legitimate prescription,” said co-author Colleen Carey, assistant professor of policy analysis and management in the College of Human Ecology. Her co-author is Thomas Buchmueller of the University of Michigan.

States that implemented a “must access” database saw a decline in the number of Medicare recipients who got more than a seven-months’ supply in a six-month period. And there was a decrease in those who filled a prescription before the previous prescription’s supply had been used.

“Doctor shopping” also dropped. Medicare opioid users who got prescriptions from five or more doctors – a common marker for “doctor shopping” – fell by 8 percent; the number of those who got opioids from five or more pharmacies declined by more than 15 percent.

On the flip side, Medicare patients appeared to evade the new regulations by traveling to a less-regulated state.

Although the study looked only at Medicare recipients, the findings are likely to translate to the general population, the researchers said. The effects were especially large for low-income disabled users and for those who obtain opioid prescriptions from a high number of doctors; both groups have the highest rates of misuse and abuse, Carey said.

The strongest effects were in states with the strictest laws, such as New York, which require doctors to check the opioid history of “every patient, every time.” But even states with laws requiring access only under certain circumstances reduced doctor shopping.

Until recently Medicare has had very few legislative tools to curtail the epidemic. And insurance companies have little incentive, because opioids are relatively cheap, costing about $1.60 per day in the study’s sample. And opioids don’t hit Medicare insurers in the bottom line, making up only 3 percent of their total drug costs, Carey said.

For information about the Medical Association prescription drug abuse awareness program, visit Smart & Safe.

Posted in: Smart and Safe

Leave a Comment (0) →